![switching between glp 1 agonists chart Outcomes in GLP-1 RA-Experienced Patients to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy glp-1_analogs [TUSOM | Pharmwiki]](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13300-021-01010-4/MediaObjects/13300_2021_1010_Fig2_HTML.png)
switching between glp 1 agonists chart Outcomes in GLP-1 RA-Experienced Patients to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy glp-1_analogs [TUSOM | Pharmwiki]
Description
For individuals with severe or complex obesity (higher BMI and significant health issues), bariatric surgery is often considered the more effective and durable treatment, especially for long-term weight maintenance and disease remission
![switching between glp 1 agonists chart Outcomes in GLP-1 RA-Experienced Patients to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
Ruggiero R, Mascolo A, Spezzaferri A, Carpentieri C, Torella D, Sportiello L, et al
![switching between glp 1 agonists chart Outcomes in GLP-1 RA-Experienced Patients to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy glp-1_analogs [TUSOM | Pharmwiki]](https://www.researchgate.net/publication/319132415/figure/tbl1/AS:670712683589662@1536921773845/Overview-of-GLP-1-Receptor-Agonists-Available-in-the-United-States-for-the-Treatment-of.png)
The structural design is tightly linked to the therapeutic profile, enabling the next generation of innovative GLP-1 RA drugs
![switching between glp 1 agonists chart Outcomes in GLP-1 RA-Experienced Patients to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy glp-1_analogs [TUSOM | Pharmwiki]](https://onlinelibrary.wiley.com/cms/asset/4d374b2a-f8a0-4047-a3bf-f315e7729fd6/ijcp13731-fig-0002-m.jpg)
Type 3 cytokines IL-17A and IL-22 drive TGF--dependent liver fibrosis
![switching between glp 1 agonists chart Outcomes in GLP-1 RA-Experienced Patients to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy glp-1_analogs [TUSOM | Pharmwiki]](https://ars.els-cdn.com/content/image/1-s2.0-S1530891X24005159-gr3.jpg)
